Welcome to our dedicated page for Archimedes Tech SPAC Partners II Co. SEC filings (Ticker: ATIIU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to track every clause hidden in Archimedes Tech SPAC Partners II Co.’s merger paperwork? SPAC disclosures span frequent 8-K updates, dense S-4 proxy statements, and quarterly 10-Q reports that can bury redemption rates and warrant terms in footnotes.
Stock Titan solves that problem. Our AI reads each new filing the moment it hits EDGAR, then drafts clear summaries so you can grasp trust-account balances, sponsor lock-ups, or any change in the proposed technology-sector business combination without wading through hundreds of pages. Whether you need the latest Archimedes Tech SPAC Partners II Co. insider trading Form 4 transactions or a quick take on the Archimedes Tech SPAC Partners II Co. quarterly earnings report 10-Q filing, the key data is surfaced in seconds.
All filing types are covered in real time:
- Form 4 insider activity—track executive stock moves before merger votes
- 10-K and 10-Q—see how trust interest income affects per-share value
- 8-K material events explained—merger announcements, PIPE financing, redemption results
- S-4 and proxy statement executive compensation—understand dilution and board remuneration post-deal
Investors use these insights to compare redemption trends across SPACs, monitor Archimedes Tech SPAC Partners II Co. Form 4 insider transactions in real time, and gauge how warrant adjustments shift upside potential. Our expert analysis coupled with AI-powered summaries turns complex disclosures into actionable knowledge—so you spend minutes, not hours, understanding the Archimedes Tech SPAC Partners II Co. annual report 10-K simplified or the latest Archimedes Tech SPAC Partners II Co. 8-K material events explained.
Archimedes Tech SPAC Partners II Co. is a blank-check company that completed its IPO on February 12, 2025, selling 23,000,000 Units (including a full 3,000,000-unit over-allotment) at $10.00 per Unit for gross proceeds of $230,000,000 and a simultaneous private placement of 840,000 Units for $8,400,000.
As of June 30, 2025 the company reports total assets of $236,897,701, comprised of $234,944,821 held in a Trust Account and $1,764,859 of cash outside the trust. Total liabilities are $8,209,120, including a deferred underwriting fee payable of $8,050,000. Ordinary shares subject to possible redemption (23,000,000 shares) are reflected at a redemption value of $234,944,821, producing shareholders' deficit of $(6,256,240).
The company had net income of $2.36 million for the quarter and $3.52 million for the six months ended June 30, 2025, driven by interest earned on trust assets of $2.49 million and $3.79 million, respectively, offset by general and administrative expenses of $130,359 and $277,020. The Company has not commenced operations, has not selected a Business Combination target, and must complete a Business Combination within the 21-month completion window or effect liquidation as described in its charter.